Modular Medical shares surge 28.39% after-hours after validating Pivot controller line for Q1 2026 insulin pump launch.

Modular Medical surged 28.39% in after-hours trading following the announcement of successful validation of its Pivot controller line for the tubeless, removable 3 milliliter patch pump. The milestone, a critical step toward its Q1 2026 commercial launch, demonstrates high-volume manufacturing readiness for the insulin delivery system targeting the $3 billion "almost-pumper" market. The news underscores the company’s ability to scale production efficiently, a key competitive advantage in the diabetes technology sector. While the Pivot remains uncleared by the FDA, the validation reduces regulatory and production risks, bolstering investor confidence in the firm’s path to commercialization. The update aligns with the stock’s sharp rise, reflecting optimism over its potential to capture market share with an affordable, user-friendly product.